CHICAGO, May 15, 2023 (Newswire.com) - The American Association of Medical Assistants® (AAMA) installed Sherry Bogar, CN-BC, CMA (AAMA), as the 2022-2023 AAMA Vice Speaker of the House at the 66th AAMA Annual Conference. In this capacity, Bogar, a resident of League City, Texas, represents medical assistants and CMAs (AAMA)® across the nation.

Medical assisting is one of the nation's careers growing much faster than the average for all occupations, according to the United States Bureau of Labor Statistics. Medical assistants work in outpatient health care settings. Employers are seeking and recruiting these allied health professionals because of their uniquely diverse clinical and administrative patient-centered training.

"It has been an honor to be chosen to continue to serve the association and profession as health care continues to evolve," says Bogar. "Credentialed medical assistants are an integral part of the care team who provide quality and safe patient care."

Bogar has served the AAMA in many capacities, including as a 2018-2022 AAMA Trustee. She has also served as the chair and member of many AAMA committees, task forces and strategy teams, including Marketing, Social Media, Partnership, Membership Development, Leadership Development, Bylaws and Resolutions, AAMA Annual Conference and Career Professional Development. In addition to being the 2022-2023 AAMA Vice Speaker of the House, she's serving as the Texas Society of Medical Assistants Speaker of the General Assembly, Website Chair and Publicity Chair.

Bogar has been a CMA (AAMA) for over 20 years. She currently works as a patient navigator at UTMB Surgical Oncology and Breast Health Clinic in League City, Texas. Bogar also serves her community as the Vice President of the Clear Creek Swim League.

The Certified Medical Assistant (AAMA)® — or CMA (AAMA) — credential represents a medical assistant who has been credentialed through the Certifying Board of the AAMA. The Certifying Board of the AAMA was awarded accreditation by the International Accreditation Service under ISO/IEC Standard 17024:2012, the global benchmark for personnel certification bodies, thus distinguishing the CMA (AAMA) from all other medical assisting certifications.

ABOUT THE AMERICAN ASSOCIATION OF MEDICAL ASSISTANTS®

The American Association of Medical Assistants®, the only organization in the world devoted exclusively to the medical assisting profession, was established in 1956 and serves the interests of more than 92,000 medical assisting professionals. The American Association of Medical Assistants provides quality resources and educational opportunities for medical assistants by offering certification, advocacy for quality patient-centered health care, credential acknowledgment and scope-of-practice protection. For more information, visit www.aama-ntl.org.

Contact Information:
Francesca Llanos
Public Relations and Marketing Manager
[email protected]
7735905524


Original Source: The AAMA installs Sherry Bogar, CN-BC, CMA (AAMA), as 2022-2023 Vice Speaker of the House

HOPKINTON, Mass., May 15, 2023 (Newswire.com) - Psyche Systems Corp, a leading provider of laboratory information software (LIS) solutions, has announced that it is dedicating resources to exploring how artificial intelligence (AI) can help improve both its internal operations and its customer service offerings.

With AI technology continuing to advance rapidly, Psyche Systems Corp. recognizes the significant potential for AI to streamline internal processes, improve data analysis, and enhance customer experience. As such, the company is investing in exploring how AI can be leveraged to achieve these goals.

"As a company at the forefront of technology in the healthcare industry, we are committed to staying ahead of the curve and leveraging the latest innovations to improve our products and services," said Ivy Cody, Director of Technical Operations at Psyche Systems Corp. "We believe that AI has the potential to revolutionize how we operate as a company and how we serve our customers, and we are excited to explore these possibilities," added Kyle Anderson, Psyche's Sales and Marketing VP. 

Some of the potential benefits of AI for Psyche Systems Corp include:

• Utilizing predictive analytics models to forecast future usage patterns, customer needs, and market trends.
• Improved data analysis capabilities, allowing for more accurate and efficient reporting and insights.
• Streamlined internal processes, reducing time and resources required for tasks such as quality control and regulatory compliance.
• Enhanced customer service, with AI-powered chatbots and other tools providing faster and more personalized support.

As part of its AI exploration, Psyche Systems Corp will be partnering with leading experts in the field to develop and test new AI-powered solutions. The company also plans to invest in employee training and development to ensure that its team is equipped with the skills and knowledge necessary to effectively utilize AI technology.

"We see AI as a key enabler of growth and innovation for our company, and we are committed to investing in this technology for the long-term benefit of our customers and our team," said Psyche's VP of Finance & Client Relations Claudia Bennett. 

About Psyche Systems Corp:

Psyche Systems Corp is a leading provider of laboratory information software (LIS) solutions for Anatomic Pathology, Toxicology, and Molecular laboratories. Founded in 1976, the company has a long history of innovation and has remained at the forefront of the industry by consistently developing cutting-edge technology and providing exceptional customer service. Psyche Systems Corp is headquartered in Hopkinton, MA, with thousands of users worldwide.

Contact Information:
Kyle Anderson
Vice President of Sales & Marketing
[email protected]
508-473-1500


Original Source: Psyche Systems Corp Dedicating Resources to Explore the Benefits of AI for Internal Operations and Customer Service

TAMPA, Fla., May 15, 2023 (Newswire.com) - Black Book Research announced that Netsmart has earned the 2023 award for highest customer satisfaction in the annual client experience performance ratings of enterprise behavioral health EHR competitors including revenue cycle management applications.

Two thousand eight hundred forty-seven psychologists, therapists, social workers, counselors, and mental health specialists participated in the crowdsourced survey from December 2022 to April 2022. Two hundred thirty-eight financial, administrative, and information technology professionals also participated in separate non-practitioner polling.

Among the user satisfaction survey respondents, groups included ambulatory psychiatric facilities; outpatient physicians, therapists, counselors, social workers, and psychologists; human services and government behavioral health agencies; and substance abuse and addiction medicine providers.

Black Book examined ambulatory behavioral health EHR adoption and usage in the U.S. and found that less than 20% of respondents consider their practices and/or organization equipped to electronically engage in care coordination, patient record exchange or population health initiatives with referral hospitals and physicians in Q2 2023, marginally up from 12 percent in pre-pandemic 2019. The growth potential for the behavioral health ambulatory technology market is estimated by Black Book to exceed 61 percent by year-end 2024, as pending value-based payment reforms require providers to exchange data electronically and coordinate care effectively, and government incentives are under consideration to incentivize mental health technology adoption and connectivity.

As the industry transforms behavioral healthcare delivery with innovations in technologies and investment funding available, over 150 start-up IT vendors specific to mental health processes were added to the Black Book user surveys directory in the past 18 months.

"Year after year, we see Netsmart as the top-rated in the mental health tech industry by client users," said Doug Brown, president of Black Book Market Research. "It's clear that, even in a tightening and increasingly complex market, Netsmart is continuing to lead the behavioral health industry by providing a product that is a vital part of their users' workflow, patient coordination, and critical digital capabilities to the successful providers in the value-based care environment."

About Black Book

Black Book Market Research LLC, its founder, management, and staff do not own or hold any financial interest in any of the vendors or public relations firms covered and encompassed in the surveys it conducts, including Netsmart. Additionally, Black Book does not contract for, barter, exchange or accept direct services from any public relations firm mentioned in the rankings. Black Book reports the results of the collected satisfaction and client experience rankings in publication and to media prior to the vendor notification of rating results and does not solicit vendor/agency participation fees, review fees, inclusion or briefing charges, consultation requirements and/or vendor collaboration as Black Book polls clients. Since 2010, Black Book Market Research LLC has polled the vendor and service firm satisfaction in the software/technology and managed services sectors around the globe. 

For methodology, auditing, resources, comprehensive research, and detailed results on the product and services rankings, see http://www.blackbookmarketresearch.com.

For more information, contact our survey team leaders at [email protected].

Contact Information:
Press Office
[email protected]
8008637590


Original Source: Behavioral Health Clinicians & Administrators Rate Netsmart as Highest in User Satisfaction, Black Book 2023 Technology Solutions Survey

AmplifyBio is adding manufacturing services, starting with cell therapy and plasmids, to its growing capabilities to support the safe development of advanced therapies.

WEST JEFFERSON, Ohio, May 15, 2023 (Newswire.com) - AmplifyBio, an emerging hub for the commercialization of advanced therapies, has announced the addition of cell therapy and plasmid manufacturing capabilities to its leading portfolio of preclinical CRO and drug characterization services. The GMP cell therapy and plasmid manufacturing labs, available in South San Francisco, are the latest step in AmplifyBio's broader strategy to build a development environment that de-risks the commercialization of next-generation therapeutics. 

AmplifyBio recently acquired from PACT Pharma, Inc, a privately held biopharmaceutical company developing neoantigen-specific T cell receptor cell therapies, certain capabilities including advanced characterization platforms, bioinformatics capabilities, and a staff of drug development experts with decades of experience in cell therapy, gene editing and immune-focused products like engineered TCR therapies. 

With today's announcement, AmplifyBio is adding a variety of manufacturing services to its development sandbox. Clients will have the option to lease GMP space in a purely "hoteling" model, send thought leadership on-site and make use of AmplifyBio's growing team of subject matter experts, or outsource development and manufacturing completely. AmplifyBio will work collaboratively to develop a size and stage-appropriate commercialization plan, including scalable and automated manufacturing. In all three collaborative service models, clients will benefit from AmplifyBio's quality management, characterization, and optimization capabilities and have the option to add integrated preclinical safety or optimization services to their projects.

"We are excited to be able to add cell therapy, gene editing manufacturing and development capabilities in a number of flexible configurations to our portfolio of services," said J. Kelly Ganjei, CEO of AmplifyBio. "This is an important milestone for us as we build a product-focused commercialization partner for advanced therapies, but it's only the beginning. Over the coming months, we will continue to add platforms for manufacturing additional modalities across our sites. Our next addition will be to add mRNA manufacturing, and we will  continue to add characterization platforms and partnerships that ensure the product stays the product, from concept to the clinic."

Cell therapies have the potential to revolutionize the treatment of various diseases and conditions, including cancer, autoimmune disorders, and genetic diseases, but their manufacture is fraught with unanticipated chemistry, manufacturing, and controls (CMC) delays, often resulting from a failure to fully characterize the drug and its function. AmplifyBio is leveraging decades of experience to provide clients with a development sandbox that avoids those delays. 

About AmplifyBio

AmplifyBio is a drug development and commercialization partner for advanced therapies with sites in West Jefferson, Ohio, and South San Francisco, California. The Ohio site provides industry-leading preclinical toxicology, safety, and pharmacology testing in an agile environment with high-level analytics capabilities to serve the dynamic safety needs of advanced therapy development. AmplifyBio's California location is dedicated to expert drug discovery, optimization, and characterization services. AmplifyBio clients can harness decades of experience in drug development, safety testing, and manufacturing support services for an end-to-end development partnership that significantly reduces costs and timelines.  

Contact Information:
Madeleine Moench
[email protected]

Kimberly LaPointe
Director of Marketing
[email protected]
19047385897


Original Source: AmplifyBio Adds Manufacturing Capabilities to Expand Service Portfolio